Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075279 | 0.82 | MAPT (0.39) | ALDH1A1GAAMAPTALOX12NPC1 | |
| SCHEMBL2610579 | 0.76 | TSHR (0.33) | — | |
| SCHEMBL12038040 | 0.76 | MME (0.34) | — | |
| SCHEMBL13313004 | 0.76 | LMNA (0.32) | — | |
| SCHEMBL21152368 | 0.73 | ALDH1A1 (0.37) | ALDH1A1GAAMAPTALOX12NPC1 | |
| SCHEMBL17532415 | 0.73 | ALDH1A1 (0.40) | ALDH1A1MAPT | |
| SCHEMBL19199460 | 0.70 | MAPT (0.37) | ALDH1A1GAAMAPTALOX12NPC1 | |
| SCHEMBL19682077 | 0.69 | TSHR (0.34) | ALDH1A1 | |
| SCHEMBL4461827 | 0.69 | MAPT (0.41) | ALDH1A1GAAMAPTALOX12NPC1 | |
| SCHEMBL20079532 | 0.68 | FOLH1 (0.36) | ALDH1A1GAAMAPTALOX12NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | ALDH1A1 4713/4885GAA 389/4885MAPT 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.